Your browser doesn't support javascript.
loading
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.
He, Qiangqiang; Qu, Meiyu; Bao, Hangyang; Xu, Yana; Shen, Tingyu; Tan, Dan; Barkat, Muhammad Qasim; Xu, Chengyun; Zeng, Ling-Hui; Wu, Ximei.
Afiliación
  • He Q; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Qu M; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China; Department of Pharmacology, Zhejiang University City College, Hangzhou 310015, China.
  • Bao H; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Xu Y; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Shen T; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Tan D; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Barkat MQ; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Xu C; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Zeng LH; Department of Pharmacology, Zhejiang University City College, Hangzhou 310015, China. Electronic address: zenglh@zucc.edu.cn.
  • Wu X; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China. Electronic address: xiwu@zju.edu.cn.
Cytokine Growth Factor Rev ; 70: 41-53, 2023 04.
Article en En | MEDLINE | ID: mdl-36934069
Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients with EGFR-sensitive mutation is the EGFR tyrosine kinase inhibitor (EGFR-TKI). However, most NSCLC patients with EGFR mutation will develop resistant mutations in EGFR-TKI therapy. With further studies, resistance mechanisms represented by EGFR-T790M mutations have revealed the impact of EGFR mutations in situ on EGFR-TKIs sensitivity. The third-generation EGFR-TKIs inhibit both EGFR-sensitive mutations and T790M mutations. The emergence of novel mutations such as EGFR-C797S and EGFR-L718Q may decrease efficacy. Searching for new targets to overcome EGFR-TKI resistance becomes a key challenge. Therefore, an in-depth understanding of the regulatory mechanisms of EGFR is essential to find novel targets to overcome drug-resistant mutations in EGFR-TKIs. EGFR, as a receptor-type tyrosine kinase, undergoes homo/heterodimerization and autophosphorylation upon binding to ligands, which activates multiple downstream signaling pathways. Interestingly, there is growing evidence that the kinase activity of EGFR is affected not only by phosphorylation but also by various post-translational modifications (PTMs, such as S-palmitoylation, S-nitrosylation, Methylation, etc.). In this review, we systematically review the effects of different protein PTMs on EGFR kinase activity and its functionality and suggest that influencing EGFR kinase activity by modulating multiple EGFR sites are potential targets to overcome EGFR-TKIs resistance mutations.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Systematic_reviews Idioma: En Revista: Cytokine Growth Factor Rev Asunto de la revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Systematic_reviews Idioma: En Revista: Cytokine Growth Factor Rev Asunto de la revista: ALERGIA E IMUNOLOGIA / BIOQUIMICA Año: 2023 Tipo del documento: Article